Skip to main content
Top
Published in: Diabetologia 3/2005

01-03-2005 | Article

Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

Authors: S. V. M. Hordern, J. E. Wright, A. M. Umpleby, F. Shojaee-Moradie, J. Amiss, D. L. Russell-Jones

Published in: Diabetologia | Issue 3/2005

Login to get access

Abstract

Aims/hypothesis

The association of insulin detemir with non-esterified fatty acid binding sites on albumin may limit its transfer from the circulation into the extravascular extracellular space in adipose tissue and muscle, due to the capillary endothelial cell barrier. In the liver, the open sinusoids may expose hepatocytes to insulin detemir, enabling it to have a greater effect in the liver than in peripheral tissues.

Methods

We investigated the effects of equipotent doses of insulin detemir and NPH insulin on hepatic glucose rate of appearance (R a), peripheral glucose rate of disposal (R d) and glycerol R a (a measure of lipolysis) using stable isotope techniques. We also investigated the effects of these insulins on NEFA concentrations in seven healthy volunteers during a 16-h euglycaemic clamp. A higher dose of insulin detemir was also studied.

Results

There was no difference in the glucose infusion profile between insulin detemir and NPH. Insulin detemir had a greater effect on mean suppression of glucose R a (mean difference 0.24 mg kg−1 min−1; CI 0.09–0.39; p<0.01), and minimum glucose R a, with minimum low dose detemir −0.10±0.15 mg·kg−1·min−1 and minimum NPH 0.17±0.10 mg·kg−1·min−1 (p<0.02). However, it had a lesser effect on mean suppression of NEFA concentrations (mean difference −0.10 mmol/l; CI −0.03 to −0.17; ANOVA, p<0.02) than NPH. The effect of insulin detemir on glucose R d and glycerol R a was not different from NPH. Following high-dose detemir, total glucose infused and maximum glucose R d were higher (p<0.02, p<0.03) and plasma NEFA concentrations lower (p<0.01) than with low-dose determir.

Conclusions/interpretation

This study suggests that insulin detemir, when compared to NPH insulin, has a greater effect on the liver than on peripheral tissues and thus has the potential to restore the physiological insulin gradient.
Literature
1.
go back to reference Bolli GB (1989) The pharmacokinetic basis of insulin therapy in diabetes mellitus. Diab Res Clin Prac 6:S3–S16CrossRef Bolli GB (1989) The pharmacokinetic basis of insulin therapy in diabetes mellitus. Diab Res Clin Prac 6:S3–S16CrossRef
2.
go back to reference Hildebrandt P (1991) Subcutaneous absorption of insulin in insulin dependent diabetic patients: influence of species, physico-chemical properties of insulin and physiological factors. Dan Med Bull 38:337–346 Hildebrandt P (1991) Subcutaneous absorption of insulin in insulin dependent diabetic patients: influence of species, physico-chemical properties of insulin and physiological factors. Dan Med Bull 38:337–346
3.
go back to reference Lauritzen T, Faber OK, Binder C (1979) Variation in 125I-insulin absorption and blood glucose concentration. Diabetologia 17:291–295 Lauritzen T, Faber OK, Binder C (1979) Variation in 125I-insulin absorption and blood glucose concentration. Diabetologia 17:291–295
4.
go back to reference Rosskamp RH, Park G (1999) Long acting insulin analogs. Diabetes Care 22:B109–B113 Rosskamp RH, Park G (1999) Long acting insulin analogs. Diabetes Care 22:B109–B113
5.
go back to reference Havelund S, Ribel U, Plum A et al (2004) The mechanism of protraction of insulin detemir, a long acting, acylated analogue of human insulin. Diabetes 53(Suppl):P462 Havelund S, Ribel U, Plum A et al (2004) The mechanism of protraction of insulin detemir, a long acting, acylated analogue of human insulin. Diabetes 53(Suppl):P462
6.
go back to reference Sonksen PH, Russell-Jones D, Jones RH (1993) Growth hormone and diabetes mellitus: a review of sixty-three years of medical research and a glimpse into the future? Horm Res 40:68–79 Sonksen PH, Russell-Jones D, Jones RH (1993) Growth hormone and diabetes mellitus: a review of sixty-three years of medical research and a glimpse into the future? Horm Res 40:68–79
7.
go back to reference Wurzburger MI, Prelevic GM, Sonksen PH, Wheeler M, Balint-Peric L (1995) Effect of recombinant human growth hormone treatment on insulin-like growth factor (IGF-I) levels in insulin-dependent diabetic patients. Acta Diabetol 32:131–134CrossRef Wurzburger MI, Prelevic GM, Sonksen PH, Wheeler M, Balint-Peric L (1995) Effect of recombinant human growth hormone treatment on insulin-like growth factor (IGF-I) levels in insulin-dependent diabetic patients. Acta Diabetol 32:131–134CrossRef
8.
go back to reference Janssen JA, Lamberts SW (2000) Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol 52:1–9CrossRef Janssen JA, Lamberts SW (2000) Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol 52:1–9CrossRef
9.
go back to reference Kruszynska YT, Home PD, Alberti KGMM (1985) Comparison of portal and peripheral insulin delivery on carbohydrate metabolism in streptozotocin-diabetic rats. Diabetologia 28:167–171 Kruszynska YT, Home PD, Alberti KGMM (1985) Comparison of portal and peripheral insulin delivery on carbohydrate metabolism in streptozotocin-diabetic rats. Diabetologia 28:167–171
10.
go back to reference Brunner GA, Sendhofer G, Wutte A et al (2000) Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH in humans. Exp Clin Endocrinol Diabetes 108:100–105CrossRef Brunner GA, Sendhofer G, Wutte A et al (2000) Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH in humans. Exp Clin Endocrinol Diabetes 108:100–105CrossRef
11.
go back to reference Kurtzhals P, Havelund S, Jonassen I et al (1995) Albumin binding of insulins with fatty acids: characterization of the ligand–protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312:725–731 Kurtzhals P, Havelund S, Jonassen I et al (1995) Albumin binding of insulins with fatty acids: characterization of the ligand–protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312:725–731
12.
go back to reference Ross M, Kaye GI, Pawlina W (2003) Histology a text and atlas. 4th ed. Lippincott Williams and Wilkins, Philadelphia, PA, pp 540–541 Ross M, Kaye GI, Pawlina W (2003) Histology a text and atlas. 4th ed. Lippincott Williams and Wilkins, Philadelphia, PA, pp 540–541
13.
go back to reference Gray H (1973) In: Warwick R, Williams PL (eds) Grays anatomy. 35th ed. Longman, Edinburgh, pp 1308–1309 Gray H (1973) In: Warwick R, Williams PL (eds) Grays anatomy. 35th ed. Longman, Edinburgh, pp 1308–1309
14.
go back to reference Reichen J (1999) The role of the sinusoidal endothelium in liver function. News Physiol Sci 14:117–121 Reichen J (1999) The role of the sinusoidal endothelium in liver function. News Physiol Sci 14:117–121
15.
go back to reference Shojaee-Moradie F, Jackson NC, Jones RH, Mallet AI, Hovorka R, Umpleby AM (1996) Quantitative measurement of 3-O methyl D glucose by gas chromatography mass spectrometry as a measure of glucose transport in vivo. J Mass Spectrom 31:961–966CrossRef Shojaee-Moradie F, Jackson NC, Jones RH, Mallet AI, Hovorka R, Umpleby AM (1996) Quantitative measurement of 3-O methyl D glucose by gas chromatography mass spectrometry as a measure of glucose transport in vivo. J Mass Spectrom 31:961–966CrossRef
16.
go back to reference Flakoll PJ, Zheng M, Vaughan S, Borel MJ (2000) Determination of stable isotopic enrichment and concentration of glycerol in plasma via gas chromatography–mass spectrometry for the estimation of lipolysis in vivo. J Chromatogr, B Biomed Sci Appl 744:47–54 Flakoll PJ, Zheng M, Vaughan S, Borel MJ (2000) Determination of stable isotopic enrichment and concentration of glycerol in plasma via gas chromatography–mass spectrometry for the estimation of lipolysis in vivo. J Chromatogr, B Biomed Sci Appl 744:47–54
17.
go back to reference Heinemann L, Sinha K, Weyer C, Loftager M, Hirsberger S, Heise T (1999) Time-action profile of the soluble fatty acid acylated long-acting insulin analogue NN304. Diabet Med 16:332–338CrossRef Heinemann L, Sinha K, Weyer C, Loftager M, Hirsberger S, Heise T (1999) Time-action profile of the soluble fatty acid acylated long-acting insulin analogue NN304. Diabet Med 16:332–338CrossRef
18.
go back to reference Steele R, Wall JS, DeBodo RC, Altszuler N (1956) Measurement of size and turnover rate of body glucose pool by isotope dilution method. Am J Physiol 187:15–24 Steele R, Wall JS, DeBodo RC, Altszuler N (1956) Measurement of size and turnover rate of body glucose pool by isotope dilution method. Am J Physiol 187:15–24
19.
go back to reference Finegood DT, Bergman RN, Vranic M (1987) Estimation of endogenous glucose production during hyperinsulinaemic–euglycaemic glucose clamps: comparison of unlabelled and labelled exogenous glucose infusates. Diabetes 36:914–929 Finegood DT, Bergman RN, Vranic M (1987) Estimation of endogenous glucose production during hyperinsulinaemic–euglycaemic glucose clamps: comparison of unlabelled and labelled exogenous glucose infusates. Diabetes 36:914–929
20.
go back to reference Sonksen P, Sonksen J (2000) Insulin: understanding its action in health and disease. Br J Anaesth 85:69–79CrossRef Sonksen P, Sonksen J (2000) Insulin: understanding its action in health and disease. Br J Anaesth 85:69–79CrossRef
21.
go back to reference Wutte A, Plank J, Sinner F et al (2004) Dose–response relationship and within subject variability of insulin detemir and NPH insulin in subjects with type 1 diabetes. Diabetes 53(Suppl):P638 Wutte A, Plank J, Sinner F et al (2004) Dose–response relationship and within subject variability of insulin detemir and NPH insulin in subjects with type 1 diabetes. Diabetes 53(Suppl):P638
22.
go back to reference Shojaee-Moradie F, Powrie JK, Sundermann E (2000) Novel hepatoselective insulin analog: studies with a covalently linked thyroxyl–insulin complex in humans. Diabetes Care 23:1124–1129 Shojaee-Moradie F, Powrie JK, Sundermann E (2000) Novel hepatoselective insulin analog: studies with a covalently linked thyroxyl–insulin complex in humans. Diabetes Care 23:1124–1129
23.
go back to reference Bergman RN (2000) Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia 43:946–952CrossRef Bergman RN (2000) Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia 43:946–952CrossRef
24.
go back to reference Andreani D (1999) Lights and shadows of insulin treatment seen by a senior diabetologist. Exp Clin Endocrinol Diabetes 107(Suppl 2):S1–S5 Andreani D (1999) Lights and shadows of insulin treatment seen by a senior diabetologist. Exp Clin Endocrinol Diabetes 107(Suppl 2):S1–S5
25.
go back to reference Mayer J (1991) Bulletin of the New England Medical Center, Volume XIV, April–June 1952: the glucostatic theory of regulation of food intake and the problem of obesity (a review). Nutr Rev 49:46–48 Mayer J (1991) Bulletin of the New England Medical Center, Volume XIV, April–June 1952: the glucostatic theory of regulation of food intake and the problem of obesity (a review). Nutr Rev 49:46–48
26.
go back to reference Friedman MI (1995) Control of energy intake by energy metabolism. Am J Clin Nutr 62(Suppl 5):1096S–1100S Friedman MI (1995) Control of energy intake by energy metabolism. Am J Clin Nutr 62(Suppl 5):1096S–1100S
27.
go back to reference Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J (2004) Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 26:724–736CrossRef Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J (2004) Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 26:724–736CrossRef
28.
go back to reference de Leeuw I, Vague P, Selam J-L et al (2002) Lower risk of nocturnal hypoglycaemia and favourable weight development in type 1 subjects after 12 months of treatment with insulin detemir vs NPH insulin. Diabetologia 45(Suppl 2):799A de Leeuw I, Vague P, Selam J-L et al (2002) Lower risk of nocturnal hypoglycaemia and favourable weight development in type 1 subjects after 12 months of treatment with insulin detemir vs NPH insulin. Diabetologia 45(Suppl 2):799A
29.
go back to reference Vague P, Selam J-L, Skeie S et al (2003) Insulin detemir is associated with more predictable glycaemic control and lower risk of hypoglycaemia compared to NPH patients with type 1 diabetes on a basal bolus regimen with pre-meal insulin aspart. Diabetes Care 26:590–596 Vague P, Selam J-L, Skeie S et al (2003) Insulin detemir is associated with more predictable glycaemic control and lower risk of hypoglycaemia compared to NPH patients with type 1 diabetes on a basal bolus regimen with pre-meal insulin aspart. Diabetes Care 26:590–596
Metadata
Title
Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp
Authors
S. V. M. Hordern
J. E. Wright
A. M. Umpleby
F. Shojaee-Moradie
J. Amiss
D. L. Russell-Jones
Publication date
01-03-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 3/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-1670-1

Other articles of this Issue 3/2005

Diabetologia 3/2005 Go to the issue